RewordedRisk Factors
To the extent our patient assistance programs or other discount policies are found to be inconsistent with applicable laws, we may be required to restructure or discontinue such programs, or be subject to other significant penalties.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, we are unable to predict the results of an increasing trend towards value based payment on our reimbursement.Therefore, Therefore, the results of our individual affiliated facilities, including facilities that are material to our results, may be volatile, which could result in a material adverse effect on our business, prospects, results of operations and financial condition.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, HHS issued a Notice of Proposed Rulemaking on January 6, 2025, which proposes changes to the HIPAA security regulations aimed at enhancing cybersecurity protections in the healthcare sector. sector; however, as of December 31, 2025, HHS had yet to publish a final rule formalizing the January 2025 proposals.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
The amounts that we receive from the Medicare and Medicaid programs for our services are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating payments or reimbursements, among other things; refinements to the Medicare Ambulatory Surgery Center payment system and refinements made by CMS to Medicare’s reimbursement policies; requirements for utilization review; and federal and state funding restrictions; any of which
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
Higher numbers of unemployed individuals generally translates into more individuals without health care insurance to help pay for procedures, thereby increasing the potential for persons to elect not to have procedures performed.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
We derived approximately 43%, 41% and 42% of our revenue from government payors, including Medicare and Medicaid programs in 2025, 2024 and 42% in both 2023 and 2022. 2023, respectively.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although most of our intercompany loans are secured by the assets of the partnership or limited liability company, LLC, the physicians and physician groups that own an interest in these partnerships and limited liability companies LLCs generally do not guarantee a pro rata amount of this debt or the other obligations of these partnerships and limited liability companies. LLCs.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
We cannot predict the effect that health care reform and other changes in healthcare laws, regulations, policies and government programs may have on our business, financial condition or results of operations.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
These authorities may also seek to exercise their supervisory or enforcement authority in new or more robust ways.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
We generally hold our ownership interests in facilities through LPs, LLPs, GPs, and LLCs or limited liability partnerships ("LLPs") in which we maintain an ownership interest along with physicians and, in some cases, both physicians and health systems.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
Reimbursement is typically conditioned on our documenting medical necessity and correctly applying diagnosis codes.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, Congress passed the One Big Beautiful Bill Act (the “OBBBA”), which introduced significant changes to federally funded healthcare programs, including Medicaid, Medicare, and the Affordable Care Act. While such changes are projected to reduce overall healthcare spending and increase regulatory burdens in certain jurisdictions in which the Company operates, they are not expected to materially impact the Company's financial statements.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
The OBBBA also makes permanent key elements of the Tax Cuts and Jobs Act including, among others, 100% bonus depreciation and the business interest expense limitations. The Company’s tax provision for the year ended December 31, 2025, incorporates the effects of these tax law changes.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
On December 16, 2025, we completed the issuance and sale of $425.0 million in aggregate principal amount of senior unsecured notes due 2032 at 101.00% of the principal amount. The notes were issued as part of the same series as the existing 2032 Unsecured Notes originally issued in April 2024, and have the same terms.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RemovedMD&A
On April 10, 2024, we completed the issuance and sale of $800.0 million in aggregate principal amount of senior unsecured notes due 2032 (the "2032 Notes"). The 2032 Notes bear interest at an annual rate of 7.250% per year, payable semi-annually on April 15 and October 15 of each year, beginning on October 15, 2024. Proceeds from sale of the 2032 Notes were used (i) to redeem all of the outstanding 2025 Notes and 2027 Notes, (ii) to pay accrued interest on the Existing Notes through, but not including, April 25, 2024, (iii) to pay related fees and expenses in connection with the offering of the 2032 Notes and redemption of the Existing Notes, and (iv) for general corporate purposes, including to fund future acquisitions.
Read it in 10-K Mar 7, 2025 at sec.govopen_in_new
RemovedMD&A
Inflation and changing prices have not significantly affected our operating results or the markets in which we operate.
Read it in 10-K Mar 7, 2025 at sec.govopen_in_new
RewordedMD&A
The increase decrease of $417.2 $319.3 million was primarily driven by the difference in the amount of net proceeds received from the issuance and sale of $425.0 million and $800.0 million in senior unsecured notes, partially offset by notes for the redemption of all the Existing Notes (as discussed in the following section). years ended December 31, 2025 and 2024, respectively.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Other service revenues include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of surgical facilities and physician practices in which we do not own an interest, management services we provide to physician practices for which we are not required to provide capital or additional assets and other non-patient services.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The increase decrease in income tax (expense) benefit expense was primarily driven by an increase in 2024 being the valuation allowance as a result of initial year the Company being was in a cumulative three-year pre-tax loss position at December 31, 2024. and thereby recorded a valuation allowance against its net operating loss carry-forward.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Net income attributable to non-controlling interests (176.8) (180.6) (147.2) (141.6) Depreciation and amortization 176.0 152.6 118.1 114.8 Interest expense, net 272.6 201.7 193.0 234.9 Equity-based compensation expense 14.8 33.3 17.7 18.4 Transaction, integration and acquisition costs (1) 108.0 64.9 48.6 73.9 100.1 61.7 De novo start-up costs 6.7 7.9 3.2 Net loss on disposals, consolidations and deconsolidations 30.4 40.6 14.4 11.1 Litigation settlements and regulatory change impact (2) 10.4 3.1 17.5 (24.7) Loss on debt extinguishment 1.3 5.1 15.5 14.9 Undesignated derivative activity (3) — — 0.6 (8.0) Other (4) — (2.7) 8.6 1.5 Adjusted EBITDA $ 526.2 $ 508.2 $ 438.1 $ 380.2
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Non-cash interest expense, net (6.5) (9.6) Non-cash lease expense (38.9) (37.8) Deferred income taxes (131.5) (16.7) Equity in earnings of unconsolidated affiliates, net of distributions received 2.0 0.8 Changes in operating assets and liabilities, net of acquisitions and divestitures 118.9 110.4 Income tax expense 134.6 18.0 Net income attributable to non-controlling interests (180.6) (176.8) Interest expense, net 201.7 272.6 Transaction, integration and acquisition costs 108.0 73.9 De novo start-up costs 6.7 Litigation settlements and other litigation costs 3.1 Other (1) (2.7) 10.4 Acquisitions and synergies (2) 58.4 (1) 52.0 Credit Agreement EBITDA $ 566.6 578.2
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The 2024 2025 Refinancing Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Second Amendment), and refinance in full all of the existing revolving credit commitments and outstanding revolving loans under the Credit Agreement (as in effect immediately prior to the Second Amendment), all as further set forth in the Second Amendment.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of revenues 2,543.7 2,368.7 2,095.8 1,964.4 General and administrative expenses 118.2 138.7 120.9 102.2 Depreciation and amortization 176.0 152.6 118.1 114.8 Transaction and integration costs 73.9 100.1 61.7 47.5 Net loss on disposals, consolidations and deconsolidations 30.4 40.6 14.4 11.1 Equity in earnings of unconsolidated affiliates (22.9) (19.5) (14.2) (12.5) Litigation settlements 7.3 (0.8) 10.6 (29.3) Loss on debt extinguishment 1.3 5.1 15.5 14.9 Other income (8.7) (20.0) (7.5) (19.0) 2,919.2 2,765.5 2,415.3 2,194.1 Operating income 389.5 348.8 328.0 345.2 Interest expense, net (272.6) (201.7) (193.0) (234.9) Income before income taxes 116.9 147.1 135.0 110.3 Income tax (expense) benefit (18.0) (134.6) 0.3 (23.3) Net income 98.9 12.5 135.3 87.0 Less:
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
(1)This amount includes diligence, transaction and integration costs related to acquisitions (both completed and in the pipeline) and divested facilities (collectively "M&A costs") of $100.1 $55.2 million, $61.7 $76.4 million and $47.5 $49.3 million for the years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, respectively.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
(1)This This amount also includes transaction other costs, including severance, IT implementation, and integration costs revenue cycle standardization of $100.1 $18.7 million, $61.7 $23.7 million and $47.5 $12.4 million for the years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, respectively.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Our income tax expense and/or other comprehensive income in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Interest expense, net was $272.6 million for the year ended December 31, 2025 compared to $201.7 million for the year ended December 31, 2024 compared to $193.0 million for the year ended December 31, 2023. 2024.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Our cash flows provided by operating activities was $274.3 million for the year ended December 31, 2025 compared to $300.1 million for the year ended December 31, 2024 compared to $293.8 million for the year ended December 31, 2023. 2024.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
Quiet changesMD&A
The fees we derive from these management arrangements are generally based on a predetermined percentage of the revenues of each surgical facility and physician network.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new